Gastroenterology
Volume 128, Issue 7 , Pages 1812-1818 , June 2005

A Randomized, Double-Blind, Controlled Withdrawal Trial in Crohn’s Disease Patients in Long-term Remission on Azathioprine

  • Marc Lémann

      Affiliations

    • Hôpital Saint-Louis, Centre Hospitalier Universitaire Lariboisière-Saint-Louis, Paris, France
    • Corresponding Author InformationAddress requests for reprints to: Marc Lémann, MD, PhD, Service de Gastroentérologie, 1 Avenue Claude Vellefaux, 75010, Paris, France. fax: (33) 1-42-49-9168
    • ,
  • Jean-Yves Mary

      Affiliations

    • Institut National de la Santé et de la Recherche Médicale ERM 0321, Paris, France
    • ,
  • Jean-Frédéric Colombel

      Affiliations

    • Hôpital Claude Huriez, Centre Hospitalier Universitaire de Lille, Lille, France
    • ,
  • Bernard Duclos

      Affiliations

    • Hôpital Hautepierre, Centre Hospitalier Universitaire de Strasbourg, Strasbourg, France
    • ,
  • Jean-Claude Soule

      Affiliations

    • Hôpital Bichat, Centre Hospitalier Universitaire Bichat-Beaujon, Paris, France
    • ,
  • Eric Lerebours

      Affiliations

    • Hôpital Charles Nicolle, Centre Hospitalier Universitaire de Rouen, Rouen, France
    • ,
  • Robert Modigliani

      Affiliations

    • Hôpital Saint-Louis, Centre Hospitalier Universitaire Lariboisière-Saint-Louis, Paris, France
    • ,
  • Yoram Bouhnik

      Affiliations

    • Hôpital Lariboisière, Centre Hospitalier Universitaire Lariboisière-Saint-Louis, Paris, France
    • ,
  • Groupe D’Etude Thérapeutique des Affections Inflammatoires du Tube Digestif (GETAID)

Received 31 July 2004 ,Accepted 2 March 2005.

References 

  1. O’Donoghue DP , Dawson AM , Powel-Tuck K , Bown RL . Double-blind withdrawal of azathioprine as maintenance treatment for Crohn’s disease . Lancet . 1978;2:944–946
  2. Candy S , Wright JP , Gerber M , Adams G , Gerig M , Goodman R . A double blind controlled study of azathioprine in the treatment and maintenance of remission in CD . Gut . 1995;37:674–678
  3. Present DH , Korelitz BI , Wisch N , Glass JL , Sachar DB , Pasternack BS . Treatment of Crohn’s disease with 6-mercaptopurine. A long-term, randomized, double-blind study . N Engl J Med . 1980;302:981–987
  4. Markowitz J , Grancher K , Kohn N , Lesser M , Daum F . A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease . Gastroenterology . 2000;119:895–902
  5. Bouhnik Y , Lémann M , Mary JY , et al.   Long-term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine . Lancet . 1996;347:215–219
  6. Fraser AG , Orchard TR , Jewell DP . The efficacy of azathioprine for the treatment of inflammatory bowel disease (a 30 year review) . Gut . 2002;50:485–489
  7. Kim PS , Zlatanic J , Korelitz BI , Gleim GW . Optimum duration of treatment with 6-mercaptopurine for Crohn’s disease . Am J Gastroenterol . 1999;94:3254–3257
  8. Fraser AG , Orchard TR , Robinson EM , Jewell DP . Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine . Aliment Pharmacol Ther . 2002;16:1225–1232
  9. Connell WR , Kamm MA , Dickson M , Balkwill AM , Ritchie JK , Lennard-Jones JE . Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease . Lancet . 1994;343:1249–1252
  10. Present DH , Meltzer SJ , Krumholz MP , Wolke A , Korelitz BI . 6-Mercaptopurine in the management of inflammatory bowel disease (short and long term toxicity) . Ann Intern Med . 1989;111:641–649
  11. Korelitz BI , Mirsky FJ , Fleisher MR , Warman JI , Wisch N , Gleim GW . Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6-mercaptopurine . Am J Gastroenterol . 1999;94:3248–3253
  12. Kumar S , Fend F , Quintanilla-Martinez L , et al.   Epstein-Barr virus-positive primary gastrointestinal Hodgkin’s disease (association with inflammatory bowel disease and immunosuppression) . Am J Surg Pathol . 2000;24:66–73
  13. Larvol L , Soule JC , Le Tourneau A . Reversible lymphoma in the setting of azathioprine therapy for Crohn’s disease . N Engl J Med . 1994;331:883–884
  14. Farrell RJ, Ang Y, Kileen P, O’Briain DS, Kelleher D, Keeling PW, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low . Gut . 2000;47:514–519
  15. Ahmed E , Fraser A , Korelitz B , Brensinger C , Lewis J . Azathioprine and 6-mercaptopurine use for inflammatory bowel disease is associated with an increased risk of lymphoma (abstr) . Gastroenterology . 2004;126:A135
  16. Posthuma EFM , Westendorp RGJ , van der Sluys Veer A , Kluin-Nelemans JC , Kluin PM , Lamers CBHW . Fatal infectious mononucleosis (a severe complication in the treatment of Crohn’s disease with azathioprine) . Gut . 1995;36:311–313
  17. Khatchatourian M , Seaton TL . An unusual complication of immunosuppressive therapy in inflammatory bowel disease . Am J Gastroenterol . 1997;92:1558–1560
  18. Connell WR , Kamm MA , Ritchie JK , Lennard-Jones JE . Bone marrow toxicity caused by azathioprine in inflammatory bowel disease (27 years of experience) . Gut . 1993;34:1081–1085
  19. Best WR , Becktel JM , Singleton JW . Rederived values of the eight coefficients of the Crohn’s Disease Activity Index (CDAI) . Gastroenterology . 1979;77:843–846
  20. Mary JY , Modigliani R . Development and validation of an endoscopic index of the severity for Crohn’s disease (a prospective multicentre study. Groupe d’Etudes Therapeutiques des Affections Inflammatoires du tube Digestif (GETAID)) . Gut . 1989;30:983–989
  21. Blackwelder WC . “Proving the null hypothesis” in clinical trials . Control Clin Trials . 1982;3:345–353
  22. Dunnett CW , Gent M . Significance testing to establish equivalence between treatments, with special reference to data in the form of 2 × 2 tables . Biometrics . 1977;33:593–602
  23. Peto R , Pike MC , Armitage P , et al.   Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples . Br J Cancer . 1977;35:1–39
  24. Byar DP . Identification of prognostic factors . In:  Buyse ME ,  Staquet MJ ,  Sylverster RJ editor. Cancer clinical trials (methods and practice) . Oxford: Oxford Medical Publications; 1988;p. 423
  25. Pearson DC , May GR , Fick GH , Sutherland LR . Azathioprine and 6-mercaptopurine in Crohn’s disease. A meta-analysis . Ann Intern Med . 1995;122:132–134
  26. Pearson DC , May GR , Fick G , Sutherland LR . Azathioprine for maintaining remission of Crohn’s disease . Cochrane Database Syst Rev . 2000; CD000067
  27. Lallemant M , Jourdain G , Le Coeur S , et al.   A trial of shortened zidovudine regimens to prevent mother-to-child transmission of human immunodeficiency virus type 1 . N Engl J Med . 2000;343:982–991
  28. The Columbus Investigators . Low-molecular-weight heparin in the treatment of patients with venous thromboembolism . N Engl J Med . 1997;337:657–662
  29. Bickston SJ , Lichtenstein GR , Arseneau KO , Cohen RB , Cominelli F . The relationship between infliximab treatment and lymphoma in Crohn’s disease . Gastroenterology . 1999;117:1433–1437
  30. Loftus EV , Tremaine WJ , Habermann TM , Harmsen WS , Zinsmeister AR , Sandborn WJ . Risk of lymphoma in inflammatory bowel disease . Am J Gastroenterol . 2000;95:2308–2312
  31. Persson PG, Karlen P, Bernell O, Leijonmarck CE, Brostrom O, Ahlbom A, et al. Crohn’s disease and cancer (a population-based cohort study) . Gastroenterology . 1994;107:1675–1679
  32. Kinlen LJ . Non-Hodgkin’s lymphoma after immunosuppressive therapy . Gut . 2000;47:462–463
  33. Lewis JD , Schwartz JS , Lichtenstein GR . Azathioprine for maintenance of remission in Crohn’s disease (benefits outweigh the risk of lymphoma) . Gastroenterology . 2000;118:1018–1024
  34. Dayharsh GA , Loftus EV , Sandborn WJ , et al.   Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine . Gastroenterology . 2002;122:72–77
  35. Modigliani R . Immunosuppressors for inflammatory bowel disease (how long is long enough?) . Inflamm Bowel Dis . 2000;6:251–257
  36. Consigny Y , Modigliani R , Colombel JF , Dupas JL , Mary JY . Biological markers of short term relapse in Crohn’s disease . Gastroenterology . 2001;120:A-141
  37. Brignola C , Iannone P , Belloli C , et al.   Prediction of relapse in patients with Crohn’s disease in remission (a simplified index using laboratory tests, enhanced by clinical characteristics) . Eur J Gastroenterol Hepatol . 1994;6:955–961
  38. Cosnes J , Beaugerie L , Carbonnel F , Gendre JP . Smoking cessation and the course of Crohn’s disease (an intervention study) . Gastroenterology . 2001;120:1093–1099

 This study was initiated, designed, and conducted by GETAID. It was funded by grant supports from the Société Nationale Française de Gastroentérologie and by the Association François Aupetit. Drugs were provided by GlaxoSmithKline. All data analysis and writing were performed independently by GETAID, without the involvement of representatives of GlaxoSmithKline.

PII: S0016-5085(05)00448-8

doi: 10.1053/j.gastro.2005.03.031

Gastroenterology
Volume 128, Issue 7 , Pages 1812-1818 , June 2005

Article Tools

* Image Usage & Resolution